TMCnet News
Global Septic Shock Pipeline Review 2016 - Research and MarketsResearch and Markets has announced the addition of the "Septic Shock - Pipeline Review, H2 2016" report to their offering. Septic Shock Septic shock is a serious condition that occurs when an overwhelming infection leads to life-threatening low blood pressure. Septic shock occurs most often in the very old and the very young. Any type of bacteria can cause septic shock. Fungi and (rarely) viruses may also cause the condition. Toxins released by the bacteria or fungi may cause tissue damage, and may lead to low blood pressure and poor organ function. Symptoms include patches of discolored skin, confusion, chills due to fall in body temperature, extreme weakness or lightheadedness. Septic Shock pipeline therapeutics constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by Companies and remaining by the Universities Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 2, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 an 1 molecules, respectively. Septic Shock - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/fc2dhz/septic_shock
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005370/en/ |
